Regina Margaret Graul - 14 Aug 2026 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: CYCN
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 17:21:27 UTC
Prior SEC filing: 07 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Regina Margaret Graul

Key filing fact

Regina Margaret Graul filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 18 Aug 2026.

Key facts

This page summarizes Regina Margaret Graul's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2026, 17:21.

Change

Previous filing in this sequence was filed on 07 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002002981 Primary reporting owner

Graul Regina Margaret

Relationship: President and Chief Executive Officer, Director
Address: C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE
Signature: /s/ Regina Margaret Graul
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCN transaction

Common Stock, no par value

Options Exercise

Transaction value
Shares: +55,849
Change %: +56%
Price: $3.30^*
Shares after: 156,152
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

CYCN transaction

Common Stock, no par value

Tax liability

Transaction value
Shares: -48,629
Change %: -31%
Price: $3.79^*
Shares after: 107,523
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYCN transaction Derivative

Option to Purchase

Options Exercise

Transaction value
Shares: -55,849
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,849
Exercise price: $3.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.

Footnote F2

The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price.

SEC remarks

President and Chief Executive Officer